Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment

Betsy Goodfellow | October 31, 2023 | News story | Medical Communications |  Allyx Therpeutics, Alzheimer’s disease, Neurology, clinical trial 

Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16^th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in Boston, US on 27 October 2023.

The study evaluated the safety, tolerability, pharmacokinetics and brain receptor occupancy of increasing doses of orally-administered ALX-001, demonstrating that all doses of the drug were well tolerated, including doses high enough to achieve full brain engagement. The results of the trial support the company’s plans to continue clinical development for Alzheimer’s Disease (AD) treatment.

The phase 1a trial saw single ascending doses given to 36 healthy adults between the ages of 50 and 80 with normal cognition. Safety findings were positive, with all doss being well-tolerated and no serious adverse events emerging.

The drug continues to show promise in additional trials building on twelve years of the company’s research. A phase 1 multiple ascending dose study in healthy volunteers is also expected to be completed in the fourth quarter of 2023.

Tim Siegert PhD, chief operating officer and co-founder of Allyx Therapeutics, commented: “The unique mechanism of action of ALX-001 at mGluR5 holds great promise as a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. We are thrilled to observe the clinical community’s response to our initial clinical data as we work to deliver a first-in-class oral therapy for people living with Alzheimer’s disease.”

Betsy Goodfellow